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Graphical abstract 
 
 
Abstract 
 
This paper describes design and evaluation of parenteral lecithin-based nanoemulsions 
intended for brain delivery of risperidone, a poorly water-soluble psychopharmacological 
drug. The nanoemulsions were prepared through cold/hot high pressure homogenization and 
characterized regarding droplet size, polydispersity, surface charge, morphology, drug–
vehicle interactions, and physical stability. To estimate the simultaneous influence of 
nanoemulsion formulation and preparation parameters – co-emulsifier type, aqueous phase 
type, homogenization temperature – on the critical quality attributes of developed 
nanoemulsions, a general factorial experimental design was applied. From the established 
design space and stability data, promising risperidone-loaded nanoemulsions (mean size 
about 160 nm, size distribution < 0.15, zeta potential around –50 mV), containing sodium 
oleate in the aqueous phase and polysorbate 80, poloxamer 188 or Solutol® HS15 as co-
emulsifier, were produced by hot homogenization and their ability to improve risperidone 
delivery to the brain was assessed in rats. Pharmacokinetic study demonstrated erratic brain 
profiles of risperidone following intraperitoneal administration in selected nanoemulsions, 
most probably due to their different droplet surface properties (different composition of the 
stabilizing layer). Namely, polysorbate 80-costabilized nanoemulsion showed increased (1.4–
7.4-fold higher) risperidone brain availability compared to other nanoemulsions and drug 
solution, suggesting this nanoemulsion as a promising carrier worth exploring further for 
brain targeting. 
 
Keywords: parenteral nanoemulsions; brain targeting; poorly water-soluble drugs; general 
factorial design; physical stability; pharmacokinetics. 
1. Introduction 
 
Despite the progress achieved in development of modern strategies for brain targeting, 
effective treatment of central nervous system (CNS) disorders still remains a complicated and 
challenging task due to the presence of a restrictive blood-brain barrier (BBB) which is a 
major obstacle to the delivery of drugs directly to the brain (Shinde et al., 2011; Wong et al., 
2012). Among the reported nanotechnological strategies, an increasing attention has been 
recently focused on nanoemulsions as potential carriers for CNS therapeutics, due to their 
attractive advantages including uniform and very small droplet size, high solubilization 
capacity for lipophilic drugs, good tolerability and greater bypass of the reticulo-endothelial 
system (RES). Additionally, an improved penetration through biological barriers, possibly 
enhanced bioavailability, controlled drug release and organ targeting could be expected with 
these systems (Shinde et al., 2011; Benita and Levy, 1993; Constantinides et al., 2008). While 
lipid nanoemulsions have been traditionally employed for parenteral nutrition and to 
solubilize and intravenously (i.v.) deliver lipophilic drugs (Li et al., 2011; Constantinides et 
al., 2008), only few reports on the nanoemulsions as carriers for parenteral delivery of drugs 
to the brain have been published up to now (Madhusudhan et al., 2007; Prabhakar et al., 
2013; Đorđević et al., 2013). 
The present paper was aimed at formulating parenteral nanoemulsions as brain drug targeting 
systems and evaluating their ability to improve the brain uptake of the incorporated drug, 
starting from analysis of the physicochemical properties of developed nanoemulsions and 
assessing their relationships with potential for brain drug delivery. For this purpose, placebo 
and drug-loaded nanoemulsions were designed with the aid of experimental design, prepared 
by high pressure homogenization (HPH) and characterized for their droplet size, size 
distribution, surface charge, viscosity, morphology, drug–vehicle interactions and stability. 
Risperidone (RSP), a poorly water-soluble “atypical” antipsychotic drug, was chosen as a 
model compound to be incorporated into nanoemulsion droplets. Commercially available 
dosage forms of RSP (conventional and orally disintegrating tablet, oral solution and long-
acting intramuscular injection) have certain drawbacks, such as swallowing problems or slow 
onset of the effect in acute psychosis or emergency situations (D’Souza et al., 2013; Rund et 
al., 2006). Although several attempts have been made to formulate various drug delivery 
systems of RSP – microemulsions (Kumar et al., 2008), polymeric nanoparticles (Muthu et 
al., 2009), solid lipid nanoparticles (Silva et al., 2012), polymeric micelles (Ould–Ouali et al., 
2005), polymeric microspheres (D’Souza et al., 2013), in situ forming matrix depot (Lin et 
al., 2011) – no studies have been reported on enhancing the brain permeability of RSP using 
parenteral nanoemulsions as drug carriers. For these reasons, the development of 
nanoemulsions intended for delivery of RSP to the brain after parenteral administration was 
of particular interest to this investigation. 
Various formulation factors (type and concentration of oils and emulsifiers), preparation 
conditions (homogenization temperature, pressure and number of cycles) as well as the way 
of drug incorporation in the inner phase of the nanoemulsion may profoundly affect its 
physicochemical properties and stability, and consequently, the in vivo pharmacokinetic 
behavior and efficacy (Benita and Levy, 1993; Nordén et al., 2001; Jumaa and Müller, 2002; 
Đorđević et al., 2013). Hence, it is highly desirable to have a good understanding and control 
of these complex parameters. Design of experiments approach has been recognized as a 
useful tool for development, improvement and optimization of nanoemulsion formulation and 
preparation, and a couple of studies using this methodology have been investigating the 
influence of formulation and/or processing variables on nanoemulsion properties and stability 
(Kelmann et al., 2007; Đorđević et al., 2013; Marín-Quintero et al., 2013). In this vein, the 
one objective of the present paper was to apply a general factorial design for identification of 
the significant main and interaction effects of experimental factors (co-emulsifier type, 
aqueous phase type and homogenization temperature) in order to find optimal conditions 
leading to the nanoemulsions with desired physicochemical features. 
Bearing in mind that nanoemulsion system on its own may affect the pharmacokinetic 
behavior of incorporated drug, and consequently its therapeutic effect (Hanefeld et al., 2012), 
the plasma and brain pharmacokinetics of RSP were studied after intraperitoneal (i.p.) 
administration of a series of nanoemulsions in rats. We wanted to know whether 
nanoemulsion composition, particularly co-emulsifier type, affects RSP pharmacokinetics, 
including brain targeting efficiency, after administration of selected RSP-loaded 
nanoemulsions via parenteral route. To the best of our knowledge, this is the first study 
conducted on formulation of RSP into parenteral nanoemulsion and on investigation of the 
influence of nanoemulsion formulation, on its own, on the delivery of RSP to the brain. As a 
result, this study could shed light on the parenteral nanoemulsions in the context of their 
further exploitation as carriers for brain drug delivery. 
 
2. Materials and methods 
 
2.1. Materials 
 
RSP was kindly donated by Zdravlje Actavis (Leskovac, Serbia). Medium chain triglycerides 
(MCT) were purchased from Fagron GmbH & KG (Barsbüttel, Germany). Soybean oil 
(Lipoid Purified Soybean Oil 700), soybean lecithin (Lipoid S 75) and sodium oleate (Lipoid 
Sodium Oleate B) were generously gifted by Lipoid GmbH (Ludwigshafen, Germany). 
Kolliphor® P 188 (poloxamer 188, PL188) and Kolliphor® HS 15 (polyoxyl/macrogol 15 
hydroxystearate, Solutol® HS 15, SHS15) were kindly supplied by BASF SE (Ludwigshafen, 
Germany). Polysorbate 80 (P80, polyoxyethylensorbitan monooleate), benzyl alcohol and 
butylhydroxytoluene (BHT) were obtained from Sigma-Aldrich Co. (St. Louis, MO, USA), 
while glycerol was provided by Merck KGaA (Darmstandt, Germany). Sodium hydroxide 
and potassium phosphate monobasic were purchased from Sigma-Aldrich Chemie GmbH 
(Steinheim, Germany). Water used in the preparation of formulations was double-distilled, 
whereas ultra-pure water, used in analyses, was obtained with a GenPure apparatus (TKA 
Wasseranfbereitungssysteme GmbH, Neiderelbert, Germany). All other chemicals and 
reagents used were of pharmaceutical or HPLC grade and used as received without further 
purification. 
 
2.2. Solubility study 
 
The solubility of RSP in pure oils (MCT and soybean oil), mixtures of oils (MCT–soybean 
oil at ratios 2:1 and 4:1, w/w) and in oil phases containing 2% (w/w) of soybean lecithin was 
determined by shake flask method (for details see Supplementary material). 
 
2.3. Preparation of nanoemulsions 
 
All nanoemulsions were prepared by cold (25 ºC) or hot (50 ºC) HPH according to the 
recently published, but slightly modified procedure (Đorđević et al., 2013). Firstly, the oil 
and the aqueous phases were separately prepared. The oil phase, consisting of 20% (w/w) of 
oil (a mixture of MCT and soybean oil at a mass ratio of 4:1), 2% (w/w) of lipophilic 
emulsifier (soybean lecithin) and 0.05% (w/w) of antioxidant (BHT), was heated at 70 ºC 
under slight magnetic stirring, until lecithin was completely dissolved. The obtained oil phase 
was then allowed to cool down to the desired production temperature (25 ºC or 50 ºC) and, 
afterward, benzyl alcohol (2%, w/w) was added. The aqueous phase was prepared by 
dissolving 2% (w/w) of hydrophilic emulsifier (P80, PL188 or SHS15) in 0.01 M phosphate 
buffer solution (PBS) (pH 9) or in double-distilled water containing 0.03% (w/w) sodium 
oleate (SOS) (pH 9). To adjust isotonicity, glycerol (2.25%, w/w) was added to the aqueous 
phase, which was kept at 25 ºC or heated to 50 ºC. 
The phases were combined by adding the aqueous phase to the oil phase, both being kept at 
the same temperature, and further pre-homogenized with a rotor-stator homogenizer (IKA 
Ultra-Turrax® T25 digital, IKA®-Werke GmbH & Co. KG, Staufen, Germany) at 10000 rpm 
for 3 min. The obtained coarse emulsion was subsequently homogenized with a high-pressure 
homogenizer (EmulsiFlex-C3, Avestin Inc., Ottawa, Canada) at 500 bar for 10 repeated 
cycles. The resulting nanoemulsion was divided into two parts that were subjected to aseptic 
filtration through 0.22 µm membrane filter or to thermal sterilization in Autoclave Series 250 
(Sutjeska, Belgrade, Serbia) at 121 °C for 15 min. When RSP was incorporated into the 
nanoemulsion, it was dissolved in benzyl alcohol as a co-solvent, and prepared solution (50 
mg/g) was added to the oil phase to obtain a final drug concentration of 1 mg/g. All 
formulations were stored in crimped glass vials at 25 ºC and one day after preparation, their 
characterization was performed. All measurements were done in triplicate. 
 
2.4. Factorial design study 
 
During the nanoemulsion development, a computer generated general factorial experimental 
design was employed to identify and estimate the effects and interactions of multiple 
formulation and preparation factors and to establish their relationships with critical quality 
attributes of developed nanoemulsions. Preliminary experiments were conducted and it was 
determined that the type of co-emulsifier and the type of aqueous phase are important 
formulation variables that can significantly affect the physicochemical properties and stability 
of nanoemulsions. On the other hand, the temperature of homogenization process was 
established to be the critical process variable which influences droplet size reduction via 
HPH. Based on these findings, the three independent variables selected for the factorial 
analysis and their respective levels were: the co-emulsifier type (A) – P80/PL188/SHS15; the 
aqueous phase type (B) – PBS/SOS; and the HPH method (C) – cold/hot (Table 1). The 
droplet size (Z-Ave), polydispersity index (PDI), and zeta potential (ZP) of nanoemulsions 
were set as the response variables. 
According to the applied general factorial design, a total of 24 experimental runs, including 2 
replicates per batch, were generated and randomly performed. The factorial design matrix and 
the responses of each experiment are given in Table 1 and Table S1 (Supplementary 
material), respectively. The general form of factorial model chosen to fit the experimental 
data can be found in Supplementary material. For building design, data processing and 
statistical analysis, the Design-Expert® software v. 9.0.1 trial (Stat-Ease Inc., Minneapolis, 
Minnesota, USA) was employed. The best polynomial models for analysis of nanoemulsions 
were proposed based on significant model terms (p < 0.05), insignificant lack of fit, multiple 
correlation coefficient (R2), and adjusted multiple correlation coefficient (adjusted R2) 
provided by Design-Expert®. Interaction plots and three-dimensional response surface plots 
displaying evaluated responses (Z-Ave, PDI, ZP) at different factor level combinations were 
also constructed. 
 
2.5. Nanoemulsion characterization 
 
2.5.1. Droplet size and size distribution analysis 
 
The mean droplet size (intensity weighted mean diameter, Z-average diameter, Z-Ave) and 
droplet size distribution (PDI) of the nanoemulsions were determined by photon correlation 
spectroscopy (PCS), using a Zetasizer Nano ZS90 (Malvern Instruments Ltd., 
Worcestershire, UK). Before measurement, each nanoemulsion sample was diluted with 
ultra-pure water or freshly prepared 0.01 M PBS (1:500, v/v). The measurements were 
performed at 25 ºC at a fixed scattering angle of 90º using a He-Ne laser at 633 nm. 
To detect a small fraction of larger emulsion droplets, laser diffractometry (LD) was applied 
as additional method for particle sizing. LD was performed using a Malvern Mastersizer 2000 
(Malvern Instruments Ltd., Worcestershire, UK) and the volume weighted diameters d(0.5), 
d(0.9) and D[4,3] were calculated as critical parameters of this part of nanoemulsion 
characterization. 
 
2.5.2. Zeta potential analysis 
 
The droplet surface charge of the nanoemulsions was determined using a Zetasizer Nano 
ZS90 (Malvern Instruments Ltd., Worcestershire, UK) by measuring the electrophoretic 
mobility of nanoemulsion droplets, which was converted to the ZP using in-built software. 
The measurements were performed at 25 ºC immediately upon appropriate dilution of 
samples (1:500, v/v) with the electrolyte solution consisted of ultra-pure water with constant 
conductivity (about 50 μS/cm) adjusted by 0.1 M PBS solution. 
 
2.5.3. Viscosity measurements 
 
Rheological behavior of selected blank and drug-loaded nanoemulsions was evaluated using 
a Visco Elite-R rotational viscometer (Fungilab S.A., Barcelona, Spain) equipped with the 
low viscosity adapter (LCP) and controlled by Supervisc software (Fungilab S.A.). The 
measurements were performed at 20 ºC within the speed range 100–200 rpm. 
 
2.5.4. Electrical conductivity measurements 
 
The electrical conductivity of all samples was determined using a sensIONTM + EC71 
conductivity meter (ShangHai Shilu Instruments Co., Ltd., Shanghai, China). The 
measurements were performed at 25 ºC by direct immersion of electrode into the sample. 
 
2.5.5. pH value measurements 
 
The pH values of all nanoemulsions were determined using a HI9321 pH meter (Hanna 
Instruments Inc., Michigan, USA). The measurements were performed at 25 ºC by direct 
immersion of pH meter glass electrode into samples. 
 
2.5.6. Atomic force microscopy 
 
To confirm the size measurements results and to visualize the morphology of the oil droplets 
in the nanoemulsions, atomic force microscopy (AFM) was employed using NTEGRA prima 
atomic force microscope (NT-MDT, Moscow, Russia). A drop (10 μL) of diluted 
nanoemulsion sample (1:100, v/v in ultra-pure water) was directly deposited onto circular 
mica substrate (Highest Grade V1 AFM Mica Discs, Ted Pella Inc., Redding, California, 
USA) and dried in vacuum to remove excess water. Measurements were carried out with the 
AFM operating in an intermittent-contact mode in air. NT-MDT NSGO1 silicon, N-type, 
Antimony doped, with Au reflective coating, cantilevers were used with the following 
parameters: nominal force constant 5.1 N/m, resonance frequency 87–230 kHz, driving 
frequency 150 kHz, and the line scanning frequency 0.5 Hz. Post-acquisition processing of 
the obtained topography and “error signal” images was performed using the software Image 
Analysis 2.2.0 (NT-MDT, Moscow, Russia). 
 
2.5.7. Differential scanning calorimetry 
 
To evaluate the physical state of RSP in formulated nanoemulsions and possible interactions 
between drug and other components, the differential scanning calorimetry (DSC) was 
performed. The DSC thermograms of individual nanoemulsion components, RSP-loaded and 
RSP-free nanoemulsions were recorded using a Mettler DSC 820 apparatus (Mettler Toledo 
GmbH Analytical, Giessen, Germany). The nanoemulsion samples were prepared by placing 
a 10 µL of the nanoemulsion into standard aluminum pan and air dried. The dried samples 
were then accurately weighed, hermetically sealed, and scanned between 25 ºC and 250 ºC at 
a heating rate of 10 ºC/min under constant nitrogen flow. An empty aluminum pan was used 
as a reference. Thermoanalytical parameters were calculated using the Mettler Toledo STARe 
software. 
 
2.5.8. Fourier transform infrared spectroscopy 
 
To investigate any chemical interaction among incorporated drug and other ingredients, the 
Fourier transform infrared (FTIR) spectroscopy was also conducted. The FTIR spectra of 
pure nanoemulsion components, RSP-loaded and blank nanoemulsions were obtained using a 
BOMEM Hartmann & Braun MB-Series FTIR spectrophotometer (ABB Bomem Inc., 
Quebec, Canada). The samples were prepared as described previously (Đorđević et al., 2013) 
and recorded between 4000 and 400 cm-1, using 10 scans for each spectrum, with a resolution 
of 4 cm-1. 
 
2.5.9. Stability study 
 
To evaluate the physical stability of developed nanoemulsions, all formulations were stored 
at room temperature for four months. The mean droplet size, PDI, ZP, viscosity, pH, and 
electrical conductivity of the nanoemulsions were determined using the previously described 
techniques. Statistical analysis of differences in measured parameters (one day after 
production and after four months of storage or after autoclaving) was performed using 
Student’s t-test. The p value of 0.05 was taken as the level of significance. 
 
2.6. In vivo pharmacokinetic study 
 
2.6.1. Experimental procedure and sample collection 
 
Pharmacokinetic properties of developed RSP-loaded nanoemulsions and RSP solution (1 
mg/mL RSP dissolved in double distilled water containing 0.25% (w/v) sodium chloride, 
0.4% (w/v) tartaric acid and sufficient sodium hydroxide to adjust the pH to 5.0), were 
assessed in male Wistar rats (Military Farm, Belgrade, Serbia). The protocol for animal 
experiments conformed to EU Directive 2010/63/EU and was approved by the Ethical 
Committee on Animal Experimentation of the Faculty of Pharmacy, University of Belgrade, 
Serbia. The rats (250–300 g) were housed in plastic cages, 4 animals per cage, on a 12 h 
light/dark period (light on at 06:00 h), under controlled conditions of temperature (22 ± 1 °C), 
relative humidity (40–70%) and illumination (120 lx). All animals were provided with pellet 
food and tap water ad libitum. 
On the day of experiment, rats were randomly divided into 6 groups, each containing 18 
animals (3 animals per each of 6 time points). The samples (RSP solution and four RSP-
loaded nanoemulsions – RSP-P80Sh, RSP-PL188Sh, RSP-SHS15Sh, and RSP-LS75Sh) were 
administered i.p. in overnight fasted animals, at a single RSP dose of 1 mg/kg, corresponding 
to an injected volume of 1 mL/kg. In addition, to determine the absolute bioavailability, one 
group of rats received 1 mg/kg RSP solution by i.v. injection into the tail vein. At 
predetermined time intervals, i.e., 5, 10, 20, 40, 60, and 180 min after dosing, the blood 
samples of rats anesthetized with ketamine (100 mg/kg, i.p.) were collected in heparinized 
syringes via cardiac puncture and centrifuged (2500 rpm, 10 min) to obtain plasma. 
Thereafter, the rat was decapitated and intact brain was carefully removed from the skull, 
weighed, homogenized in 5 mL of methanol (IKA Ultra-Turrax® T25 digital), and 
homogenates were centrifuged at 6000 rpm for 20 min (Centrifuge MPW-56, MPW Med. 
Instruments, Warszawa, Poland). 
 
2.6.2. Determination of risperidone concentration in rat plasma and brain tissue 
 
To determine the concentration of RSP in plasma and supernatants of brain tissue 
homogenates, RSP was extracted from these samples by solid phase extraction according to 
the previously reported procedure (Ðorđević et al., 2013). Concentration of RSP in the 
resulting eluates were determined by ultra-high performance liquid chromatography-tandem 
mass spectrometry (UHPLC-MS/MS). Details are provided in Supplementary material. 
 
2.6.3. Pharmacokinetic analysis 
 Non-compartmental pharmacokinetic analysis in plasma and brain after i.p. administration of 
RSP-loaded nanoemulsions and i.p. as well as i.v. administration of RSP solution was 
performed with PK Functions for Microsoft Excel software (Usansky, Desai and Tang-Liu, 
Department of Pharmacokinetics and Drug Metabolism, Allergan, Irvine, CA; 
http://www.boomer.org/pkin/soft.html). The following pharmacokinetic parameters were 
calculated: maximum concentration (Cmax), time to reach maximum concentration (Tmax), area 
under the concentration versus time curve from zero to last measurable time point (AUC0–t), 
terminal elimination half-life (t1/2), and clearance (CL = Dose/AUC0–t). 
The relative bioavailability (Frel) and absolute bioavailability (Fabs) of RSP following i.p. 
administration in nanoemulsions were determined relative to the i.p. and i.v. solution, 
respectively using the formula: F = AUC0–t, RSP nanoemulsion/AUC0–t, RSP solution. The brain 
targeting potential of developed RSP-loaded nanoemulsions after i.p. administration was also 
evaluated using the parameters such as brain-to-plasma drug concentration ratio, brain-to-
plasma partition coefficient (Kp = AUC0-t, brain/AUC0-t, plasma), and therapeutic availability (TA 
= AUC0-t, brain, RSP nanoemulsion/AUC0-t, brain, RSP solution). The values of these parameters greater 
than 1 indicated good brain targeting of the formulation. 
 
2.7. Statistical analysis 
 
The results of the in vivo studies are shown as mean parameter value ± standard error of the 
mean (SEM) of three independent experiments. Whenever applicable, statistical differences 
between multiple groups were determined by one-way ANOVA with post hoc analysis using 
Tukey’s HSD test for pairwise comparisons between groups. When the assumptions of 
ANOVA were not met, i.e., the variances of the groups were not equal, and the data could not 
be transformed, a nonparametric Kruskal–Wallis test (one-way ANOVA by ranks) was 
performed and, in the case of significant difference, the nonparametric Mann–Whitney U test 
was used for pairwise group comparisons. Statistical analyses were performed using PASW 
Statistics software package, version 18.0 (SPSS Inc., Chicago, USA). The level of 
significance was set at p < 0.05. 
 
3. Results and discussion 
 
3.1. Preparation and characterization of nanoemulsions 
 
The solubility of the drug in the internal oil phase is an important factor to consider when 
designing nanoemulsions as carriers for lipophilic drugs (Benita and Levy, 1993). RSP is a 
poorly water-soluble drug and thus it is essential to incorporate it in the oil core of 
nanoemulsion in order to successfully exploit the nanoemulsion advantages in brain drug 
delivery. Hence, to select the optimal oil phase for the formulation of the nanoemulsions, 
RSP solubility in two oils commonly used in commercial parenteral lipid emulsions, namely 
MCT and soybean oil, as well as in their mixtures, was investigated. The solubility of RSP in 
tested oils and mixtures of oils was very low (≤ 2.2 mg/mL at 25 °C), suggesting inefficient 
drug loading in the nanoemulsion with a fixed amount (20%, w/w) of oil phase. 
As the target concentration of 1 mg/g RSP in the nanoemulsion was unattainable, the efforts 
have been made to solve the problem of the poor RSP solubility. Firstly, lecithin was added 
as a solubilizer to the oil/mixture of oils and, secondly, temperature elevation method was 
applied. The addition of lecithin did not result in the dissolution of appreciable amounts of 
drug – solubility was about 2 mg/mL at 25 °C. Although drug dissolution in the oil phase 
containing lecithin was achieved by heating, drug precipitation was observed after cooling to 
the room temperature. Finally, an oil-miscible co-solvent, benzyl alcohol, was introduced in 
the formulation, and by dissolving RSP in this co-solvent it was possible to obtain a 1 mg/g 
concentration of the active, without the formation of drug crystals in the nanoemulsion. 
Regarding the oil phase selection, it has been reported that the mixture of MCT and long 
chain triglyceride (LCT) such as soybean oil can reduce the viscosity of LCT, nanoemulsion 
droplet size distribution as well as interfacial tension and, hence, might promote physical 
stability of nanoemulsions (Driscoll et al., 2000). Considering this and our experience with 
diazepam-loaded nanoemulsions (Đorđević et al., 2013), the mixture of MCT and soybean oil 
(4:1, w/w) was chosen as the oil phase for the formulation of unloaded and RSP-loaded 
nanoemulsions. 
Based on previous experiments (Ma et al., 2013; Đorđević et al., 2013), the soybean lecithin 
was selected as the main emulsifier for nanoemulsion preparation in the present study. 
Furthermore, in order to improve the stability of nanoemulsions during storage and thermal 
sterilization, different types of co-emulsifiers, that form a close-packed, complex film with 
lecithin at the oil-water interface, were also employed. Selection of co-emulsifiers was 
carried out in accordance with their acceptability for parenteral administration and, more 
importantly, with our final goal – brain drug delivery. We selected P80, PL188 and SHS15, 
as promising functional excipients that have shown tendency to enhance brain uptake of 
drugs by acting as P-glycoprotein inhibitors, permeation enhancers, stealth agents or 
promoters of receptor-mediated endocytosis (Kreuter, 2001; Batrakova and Kabanov, 2008; 
Shinde et al., 2011; Kasongo et al., 2011). 
To avoid pH alterations during storage and to keep RSP as a weak base in the oil phase, a 
0.01 M PBS (pH 9) and double-distilled water containing sodium oleate (SOS) (pH 9) were 
used as the aqueous phases of the nanoemulsions. Besides the role of an auxiliary stabilizer of 
the phospholipid surface layer (Shi et al., 2009; Werling et al., 2008), sodium oleate also 
served as a buffering agent to maintain the pH of prepared nanoemulsion formulations to a 
desirable value. 
A total of 12 different unloaded nanoemulsion formulations were prepared using cold or hot 
HPH, concordant with applied experimental design (Table 1). The resulting nanoemulsions 
were highly fluid and homogenous with milky-white appearance. Representative 
nanoemulsion parameters (Z-Ave, PDI, ZP, pH and electrical conductivity) one day after 
preparation and after four months of storage at room temperature, as well as after 
autoclaving, are presented in Table S1 (see Supplementary material). The PCS particle size 
analysis (Table S1, Supplementary material) confirmed that the mean droplet size of all 
prepared unloaded nanoemulsions was in nanometer range (107–194 nm), with a relatively 
narrow particle size distribution (PDI < 0.15), suggesting that the developed nanoemulsions 
were suitable for parenteral application. In addition, all formulations revealed negative ZP 
values, ranged from –43 to –59 mV (Table S1, Supplementary material), implying a 
sufficiently high negative surface charge for droplet-droplet repulsion and thus an enhanced 
nanoemulsion stability. 
 
3.2. Factorial design study 
 
It has been proposed that nanoemulsion droplet size, ZP and surface properties are the key 
parameters affecting the BBB passage, with the surfactant/emulsifier composition playing the 
most important role in this regard (Müller and Göppert, 2007; Keck et al., 2013; Voigt et al., 
2014). Based on prior reports (Blasi et al., 2013; Dhawan et al., 2011; Wohlfart et al., 2012), 
we specifically assumed that the small (below 200 nm) and homogenous droplet size, 
negative ZP and hydrophilic droplet surface are prerequisites for efficient brain targeting and 
utilized the experimental design strategy to uncover the influence factors for these 
parameters. More precisely, with the purpose of gaining better perception of how 
nanoemulsion critical properties are affected by variations of nanoemulsion composition 
(aqueous phase and co-emulsifier type) and preparation conditions (homogenization 
temperature), general factorial experimental design was applied, that allowed to elucidate 
various interactions between independent variables tested, which are not possible to detect 
with the traditional one-factor-at-a-time method. 
Table S1 (Supplementary material) shows the results of measured responses for all unloaded 
nanoemulsions that were part of the general factorial design to establish the combination of 
variables and their interactions yielding nanoemulsions with desirable properties for brain 
drug targeting. For each dependent variable (Z-Ave, PDI, and ZP), the effects corresponding 
to the investigated factors (co-emulsifier type, aqueous phase type, and HPH method) and 
interactions were calculated. Factors and interactions with p < 0.05 were considered 
significant. The terms with insignificant influence on estimated responses were excluded, 
except those required to maintain hierarchy, and thus the reduced factorial models for 
nanoemulsion droplet size, size distribution and surface charge were generated. The resulting 
final response equations in terms of coded factors are given below: 
 
     
         BCABCABCCACABA
BACBAAnmZAve
237.5130.010.6266.4147.0285.3
121.242.2341.6231.6167.245.164)(


   (1) 
 
     
       
 BCA
BCABCCACABA
BACBAAPDI
20031.0
10083.00024.020045.010078.020070.0
10086.00120.00065.020045.010077.01100.0


  (2) 
 
     
  BCBA
BACBAAmVZP
20.1225.2
102.194.286.1276.0181.052.50)(


   (3) 
 The ANOVA showed the generated models for Z-Ave, PDI and ZP to be highly significant (p 
< 0.0001 for model F values) with non-significant lack of fit (p > 0.01; could be calculated 
only for ZP). The fitted models had high R2, adjusted R2, and adequate precision values (Z-
Ave: 0.9982, 0.9966, 76.229; PDI: 0.9280, 0.8620, 14.028; ZP: 0.9388, 0.9120, 18.78, 
respectively), indicating that three listed responses are well described by the proposed 
models. 
Fig. 1a shows the Pareto plot for the mean droplet size (Z-Ave) of nanoemulsions. The 
smaller the p value or, in other words, the higher the magnitude of each coefficient, the 
higher is the respective effect on the response. Nanoemulsion droplet size was significantly 
affected by all factors under study (p < 0.0001) with the following order: HPH method (C) > 
aqueous phase type (B) > co-emulsifier type (A) (Fig. 1a). Moreover, the interactions 
between these factors (co-emulsifier type/aqueous phase type – AB; co-emulsifier type/HPH 
method – AC; aqueous phase type/HPH method – BC) were also found to influence the Z-
Ave of nanoemulsions at a significant level (p < 0.0001), with the BC interaction having the 
most pronounced effect. 
A negative sign for the coefficient of HPH method in Eq. (1) represented an antagonistic 
effect on Z-Ave, meaning that the droplet size of nanoemulsions made at 50 °C (hot HPH) 
was smaller compared to those prepared at 25 °C (cold HPH). This may mean that the higher 
energy input during homogenization by increasing the production temperature from 25 °C to 
50 °C caused a decrease in viscosity as wall as in the interfacial tension, which is expected to 
facilitate the production of smaller nanoemulsion droplets (Floury et al., 2000). The type of 
aqueous phase revealed a positive influence on the Z-Ave of nanoemulsions (Eq. (1)): the 
smaller droplet size was found to correlate with PBS, while the aqueous phase containing 
sodium oleate (SOS) produced nanoemulsions with larger droplet sizes. The choice of co-
emulsifier showed a quite different trend of influence on Z-Ave (Table S1, Supplementary 
material). While SHS15 appeared to yield nanoemulsions with smaller droplets, the impact of 
the co-emulsifier type on the nanoemulsion droplet size could be better understood through 
interpreting the significant two-factor interactions. 
When analyzing AB interaction (Fig. 2), it is apparent that at lower processing temperature 
(cold HPH), no difference in droplet size of nanoemulsions prepared with different co-
emulsifiers (P80, PL188, and SHS15) was observed, when PBS was used as an aqueous 
phase. In case of nanoemulsions produced with SOS as the aqueous phase, the Z-Ave of 
nanoemulsions containing SHS15 as co-emulsifier was lower than that of nanoemulsions 
costabilized by P80 or PL188, which had similar droplet sizes. Furthermore, when SOS was 
used instead of PBS, the Z-Ave of P80- and PL188-costabilized nanoemulsions tended to 
slightly increase, whereas in case of SHS15-nanoemulsions a lower Z-Ave was obtained (Fig. 
2). At higher homogenization temperature (hot HPH), using SOS instead of PBS as the 
aqueous phase resulted in the increase of Z-Ave for all nanoemulsions, regardless the co-
emulsifier used (Fig. 2). When comparing the influence of coemulsifier type on Z-Ave of 
nanoemulsions prepared at 50 C with PBS as the aqueous phase, it can be noticed that 
PL188 produced nanoemulsions with larger droplets, whereas lower size was obtained with 
P80 and SHS15. Conversely, when SOS was used as the aqueous phase, the Z-Ave obtained 
for P80- and PL188-nanoemulsions was comparable and greater than droplet size of SHS15-
nanoemulsions. The same trends regarding nanoemulsion Z-Ave could be also observed by 
analyzing the effects of AC and BC interactions (Fig. 2). 
To obtain information about the homogeneity of nanoemulsions droplet sizes and, hence, 
about the quality of prepared nanoemulsion samples, the droplet size distribution (PDI) and 
its dependence on the factors varied was assessed, and results obtained from the model fitting 
procedure are shown in Eq. (2) and Fig. 1b. The PDI of nanoemulsions was significantly 
influenced by the individually tested variables as well as by their combined effects. The HPH 
method appeared to have an inverted but the greatest influence on PDI, imposing that a 
higher homogenization temperature produced nanoemulsions with more homogenous sizes 
(lower PDI). The type of co-emulsifier was also found to be critically important in variations 
of nanoemulsion PDI and, more importantly, to strongly interact with other two factors, 
namely aqueous phase type and HPH method – AB and AC interaction, respectively (Fig. 3). 
It could be noticed that in case of nanoemulsions containing PBS as aqueous phase, the type 
of co-emulsifier influenced the PDI of nanoemulsions following the trend of PDIP80 < 
PDIPL188 < PDISHS15 and PDIP80 > PDIPL188 > PDISHS15 for nanoemulsions prepared with cold 
and hot HPH method, respectively. Conversely, when SOS was employed as the aqueous 
phase, P80 seemed to yield nanoemulsions with the largest PDI, whereas nanoemulsions 
derived from PL188 showed the lowest PDI values (PDIP80 > PDISHS15 > PDIPL188), 
irrespective of applied production temperature (Fig. 3). Moreover, when SOS was used 
instead of PBS as aqueous phase at lower production temperature (cold HPH), a tendency of 
PDI increase was shown in P80-based nanoemulsions, contrary to the SHS15-based 
nanoemulsions where PDI tended to decrease, while no difference was observed in PDI of 
PL188-based nanoemulsions. On the other hand, use of SOS instead of PBS at higher 
homogenization temperature (hot HPH) resulted in more heterogeneous droplet sizes for P80- 
and SHS15-nanoemulsions, whereas the PDI of PL188-nanoemulsions was only negligibly 
decreased (Fig. 3). When PBS was used as the aqueous phase, an increase of homogenization 
temperature from 25 C to 50 C induced an increase in PDI for P80-based nanoemulsions, 
whereas the PDI of PL188- and SHS15-nanoemulsions decreased. The variation in 
production method was the most effective in changing the PDI of nanoemulsions with SHS15 
as co-emulsifier. However, in case of SOS-nanoemulsions, variation in temperature from 25 
C to 50 C resulted in reduction of PDI of all nanoemulsions, irrespective of co-emulsifier 
used (Fig. 3). 
Considering the ZP, Fig. 1c reveals that all the studied factors were significant and also 
positive (Eq. (3)), imposing a linear decreasing effect on the ZP of nanoemulsions. In 
addition, significant interactions were identified between co-emulsifier type and aqueous 
phase type (AB) and between aqueous phase type and HPH method (BC), as presented in Fig. 
4. Judging from the value of coefficients in Eq.(3), the HPH method had the largest influence 
on nanoemulsion ZP – more negative ZP values were obtained when cold homogenization 
process was performed as compared to hot HPH method. It could be due to the larger droplet 
size of nanoemulsions prepared at 25 C and, consequently, the smaller total surface area 
available for adsorption of surfactant molecules compared to formulations made at 50 C. As 
a result, at a given concentration of surfactants in the formulation, more surfactant molecules 
are expected to be adsorbed per unit area in case of larger droplets leading to greater negative 
charge and, hence, more negative ZP values (cf. Verna et al., 2009). The factors interactions 
shown in Fig. 4 supported the above findings. It is obvious that the ZP of all nanoemulsions 
prepared with either PBS or SOS as aqueous phase in combination with any of the three co-
emulsifiers (P80, PL188 or SHS15) decreased when HPH method was changed from cold to 
hot, with reduction in ZP more pronounced in PBS nanoemulsions. Likewise, the lower ZP 
values were obtained for all nanoemulsions prepared with cold HPH when using SOS instead 
of PBS as aqueous phase. In case of hot HPH, the ZP of P80- and SHS15-based 
nanoemulsions increased (became more negative), whereas in PL188-based formulations 
decreased, when SOS was used instead of PBS (Fig. 4). 
 
3.3. Stability study – unloaded nanoemulsions 
 
The physical stability of all unloaded nanoemulsions prepared according to the design of 
experiments was investigated after 4 months of storage at 25 °C as well as after heat 
sterilization by autoclaving (121 C, 15 min). Data generated from the stability study (Table 
S1, Supplementary material) showed that the droplet size, PDI, and ZP – the most 
representative parameters in the control of emulsion stability – stayed practically unchanged 
during 4 months of storage for almost all investigated non-autoclaved nanoemulsion samples. 
A significant increase in droplet size of about 40–50 nm (p < 0.05) was only found for 
nanoemulsions formulated with PBS as aqueous phase and SHS15 as coemulsifier, prepared 
by either cold or hot HPH, but no visible free oil or phase separation was seen on visual 
inspection. 
In addition, results given in Table S1 (see Supplementary material) revealed that the physical 
stability of all nanoemulsions produced with PBS was significantly altered during 
autoclaving. For example, for P80-costabilized nanoemulsions containing PBS, the complete 
phase separation due to energy-induced coalescence of oil droplets was observed. 
Nanoemulsions costabilized by PL188 demonstrated significant changes (p < 0.05) in the 
stability parameters: increase in Z-Ave, decrease in PDI, and increase in absolute ZP. Also, in 
nanoemulsions with SHS15, significant reduction of Z-Ave and PDI was detected upon 
autoclaving, but the size increased significantly (p < 0.05) with time. In contrast to the 
formulations with PBS, all investigated nanoemulsions containing SOS, irrespective of co-
emulsifier type or preparation method, remained unchanged upon autoclaving in terms of 
droplet size, PDI, and charge, and the parameter values were stable within 4 months of 
storage at 25 C. Thus, the stability of nanoemulsions against heat-stress during autoclaving 
was possibly promoted by the presence of sodium oleate which, in addition to pH buffering, 
might increase the negative charge of the droplet surface layer, contributing to the 
nanoemulsion electrostatic stabilization (Werling et al., 2008). 
Additional information about storage stability and heat sterilization stability of investigated 
nanoemulsions was derived from the changes in pH and electrical conductivity over the 
evaluated period. The pH of most nanoemulsion samples significantly decreased (p < 0.05, 
Table S1, Supplementary material) during storage and autoclaving, but the pH values were 
still between 7 and 8, reflecting physiological compatibility and suitability for parenteral 
application. Concerning the electrical conductivity, slight but significant increases or 
decreases (p < 0.05, Table S1, Supplementary material) as a function of time and autoclaving 
were observed, but correlation between the change of this parameter and nanoemulsion 
instability was absent. 
In summary, the results of stability investigation confirmed that the factors influencing 
nanoemulsion stability were the type of aqueous phase and the type of co-emulsifier. 
Combining all the stability parameters, we can conclude that nanoemulsions containing 
sodium oleate in aqueous phase (SOS) were more robust and more stable than those with 
PBS and they were considered as promising carriers for parenteral drug delivery. 
 
3.4. Risperidone-loaded nanoemulsions – characterization and stability evaluation 
 
According to data on polymeric and solid lipid nanoparticles (Blasi et al., 2013; Dhawan et 
al., 2011; Martins et al., 2012), the nanoemulsions with droplet sizes in the range of 100–200 
nm were expected to have prolonged blood circulation time and hence potential increase in 
time for which the droplets remain in contact with the BBB and can be endocytosed by the 
brain blood vessel endothelial cells (Kreuter, 2001; Kreuter, 2005). Generally, the 
nanoemulsions with mean droplet diameter smaller than 200 nm, narrow droplet size 
distribution (PDI < 0.15) and sufficiently high negative surface charge (about –50 mV) were 
obtained within the design space in our study. Since in terms of physicochemical parameters 
all designed nanoemulsions were appropriate for brain drug delivery, the most suitable 
formulations for drug incorporation were selected as a function of the smallest droplet size, 
the lowest size distribution and the highest stability for at least 4 months of storage at 25° C 
as well as upon autoclaving. In addition, knowing that the particle surface chemistry may take 
precedence over the droplet size and surface charge in determining BBB passage (Voigt et 
al., 2014), the type of co-emulsifier was also considered as a relevant factor in the selection 
between the unloaded nanoemulsions. 
Three most promising formulations prepared by hot HPH, differing in the co-emulsifier (P80, 
PL188 or SHS15) and containing SOS as aqueous phase, were loaded with RSP and their 
comprehensive evaluation was performed. Table S2, provided in the Supplementary material, 
displays the physicochemical characteristics of selected RSP-loaded (RSP-P80Sh, RSP-
PL188Sh, RSP-SHS15Sh) compared to corresponding unloaded nanoemulsions (P80Sh, 
PL188Sh, SHS15Sh) 1 day after production and after 4 months of storage at 25 °C. The RSP-
loaded nanoemulsions behaved almost identically with respect to mean droplet size (Z-Ave 
around 160 nm), size homogeneity (PDI in the range of 0.10–0.13) and surface charge (ZP 
values about –50 mV). Supplementary LD particle size analysis confirmed that the droplet 
diameters of these RSP-loaded nanoemulsions were in nanometer range (d(0.5) about 170 
nm; d(0.9) around 200 nm) with no particles above 1 µm, proving their feasibility for 
parenteral administration and brain drug delivery. Furthermore, the pH values (8.2–8.4) and 
sufficiently low viscosity (6 to 11 mPa·s) additionally demonstrated the suitability of 
developed RSP-loaded nanoemulsions for parenteral use. 
The comparison of drug-loaded with corresponding unloaded nanoemulsions revealed that 
the incorporation of RSP did not significantly alter the nanoemulsion droplet size, size 
distribution and surface charge, with one exception (see Table S2 in the Supplementary 
material): the mean size of the SHS15-based RSP-loaded nanoemulsion (RSP-SHS15Sh) was 
slightly (about 10 nm), but significantly (p < 0.05), higher than that of corresponding plain 
formulation (SHS15Sh), suggesting that the RSP might have been localized predominantly in 
the oil core of the nanoemulsion. On the other hand, it could be noticed that RSP contributed 
significantly (p < 0.05) to higher pH, higher electrical conductivity, and lower viscosity of the 
nanoemulsions (Table S2, Supplementary material), which might be related to the putative 
presence of a portion of drug molecules in the oil/water interface of the loaded 
nanoemulsions. Concerning the storage stability, all RSP-loaded nanoemulsions were found 
to be stable after four months, with only minor variations in measured physicochemical 
parameters (see Table S2 in the Supplementary material). 
 
3.5. Drug–vehicle interactions and nanoemulsion characterization by DSC, FTIR, and 
AFM 
 
The effect of drug loading on thermal behavior and structural properties of developed 
nanoemulsions as well as potential interactions among ingredients were examined using DSC 
technique. To avoid water evaporation event (broad endothermic peak around 100 ºC) and its 
influence on the nanoemulsion thermograms analysis, the native nanoemulsion samples were 
air-dried before DSC measurements. Fig. 5a displays the DSC thermal curves obtained for 
selected blank and RSP-loaded nanoemulsions, as well as for pure RSP. The DSC 
thermogram of pure RSP showed a sharp endothermic peak at 171.67 ºC, corresponding to 
the melting of the drug. In the DSC curves of both, RSP-loaded and unloaded nanoemulsions, 
a broad asymmetric endothermic peak was observed around 190 ºC, most likely due to benzyl 
alcohol evaporation. However, for RSP-containing nanoemulsion, no melting peak of the 
drug was detected, suggesting that RSP was molecularly dispersed, i.e., dissolved in the oil 
phase of the nanoemulsion. 
To complement the findings of the thermal analysis, the FTIR spectroscopy was employed as 
a supplementary technique to find out possible intermolecular interactions between the drug 
and other components in the developed nanoemulsion systems. Fig. 5b shows the FTIR 
spectra of selected RSP-loaded and corresponding blank nanoemulsion, as well as of pure 
RSP, MCT–soybean oil mixture (4:1, w/w), and soybean lecithin (full description of 
characteristic absorption bands is provided in Supplementary material). The FTIR profile of 
nanoemulsion loaded with RSP did not show specific peaks corresponding to the drug, i.e., 
the described RSP peaks disappeared or were hidden under the peaks of oils. Also, no new 
peaks or shifts could be detected in this spectrum when compared with the FTIR spectrum of 
blank nanoemulsion, confirming the absence of any chemical interaction of RSP with other 
nanoemulsion ingredients. These results were in line with those obtained by DSC, indicating 
that RSP was uniformly dispersed, without any intermolecular drug–vehicle interaction or 
any hints of possible drug recrystallization in the nanoemulsions. 
As a further part of nanoemulsion characterization, AFM analysis was performed to complete 
information about droplet size, size distribution, morphology, and the possible aggregation 
process within the system. The AFM images – error signal, 2D and 3D topography, obtained 
for 2  2 μm2 area of the selected RSP-loaded nanoemulsion sample (RSP-P80Sh) are 
illustrated in Figs. 6a, 6b, and 6c, respectively, whereas the height profiles of two marked 
nanodroplets are given in Fig. 6d. These AFM photomicrographs clearly showed the 
formation of spherical nanosized homogenous droplets, with the mean diameters compatible 
with those determined by PCS and LD. Most importantly, no presence of larger droplets, 
aggregates or undissolved drug crystals was detected in the investigated nanoemulsion 
samples. 
 
3.6. In vivo pharmacokinetic study 
 In order to evaluate the potential of the developed nanoemulsion carriers to deliver the model 
drug to the brain through the parenteral route, and to shed light on the specific role of 
nanoemulsion surface properties in brain drug targeting, the in vivo pharmacokinetic studies 
were performed in rats. Besides three selected RSP-loaded nanoemulsions (RSP-P80Sh, RSP-
PL188Sh, and RSP-SHS15Sh), stabilized by lecithin in combination with P80, PL188, and 
SHS15 as co-emulsifiers, respectively, the co-emulsifier-free nanoemulsion formulation 
containing 2% (w/w) of lecithin, loaded with RSP (1 mg/g), was also prepared to assess the 
influence of the used co-emulsifier on the RSP pharmacokinetics. The physicochemical 
characteristics and stability data of this control nanoemulsion, RSP-LS75Sh, are described in 
Table S2 (Supplementary material). RSP content in all tested nanoemulsions was determined 
spectrophotometrically using corresponding blank, and the values were 100.7 ± 3.9, 100.1 ± 
2.2, 100.7 ± 1.8, and 100.8 ± 2.9% for RSP-P80Sh, RSP-PL188Sh, RSP-SHS15Sh, and RSP-
LS75Sh, respectively. 
The concentration–time profiles of RSP in rat plasma and brain after i.p. administration of 
selected RSP nanoemulsions and RSP solution, along with their brain-to-plasma 
concentration ratios, are presented in Fig. 7, and the calculated pharmacokinetic parameters 
are summarized in Table 2. As the graphs show (Fig. 7), the mean plasma concentrations of 
RSP tended to be higher with nanoemulsions than with solution at the later time points (1–3 h 
post-injection), or in the case of RSP-P80Sh at all time points, with significant difference 
(F(4,10) = 10.977, p = 0.001) observed at 3 h post-injection for RSP-P80Sh, RSP-PL188Sh, 
and RSP-SHS15Sh nanoemulsions compared to control RSP solution. The possible 
explanation may be the formation of RSP depot at the i.p. injection site after administration 
of nanoemulsions, as well as slow release of incorporated RSP from the nanoemulsion oil 
core into the blood, since the loaded drug needs time to transfer from the oil phase to the 
aqueous phase of nanoemulsion (Chen et al., 2010; Lu et al., 2009). 
In addition, the mean plasma RSP concentrations after i.p. injection of nanoemulsions RSP-
P80Sh, RSP-PL188Sh, and RSP-SHS15Sh were higher than those after control nanoemulsion 
formulation RSP-LS75Sh at most of time points (significant at 20 min (F(4,10) = 16.788, p < 
0.001) and 180 min (F(4,10) = 10.977, p = 0.001) post-injection for RSP-P80Sh vs. RSP-
LS75Sh and RSP-PL188Sh vs. RSP-LS75Sh), probably due to the smaller size of RSP-
P80Sh, RSP-PL188Sh, and RSP-SHS15Sh nanoemulsion droplets coated with more 
hydrophilic surfactant film (due to the presence of co-emulsifier) compared to RSP-LS75Sh 
formulation, resulting in their prolonged retention in circulation and greater avoidance of the 
RES. 
Although no significant differences were found in any of the studied plasma pharmacokinetic 
parameters (Cmax, Tmax, AUC0–t, CL, t1/2) of RSP from various vehicles, some trends could be 
recognized. For example, after i.p. injection, all nanoemulsions as well as solution showed 
similar mean plasma Cmax values of RSP which were reached within 5–20 min, suggesting 
relatively rapid absorption into systemic circulation and subsequent fast distribution into the 
brain, with exception of nanoemulsions RSP-P80Sh and RSP-PL188Sh, both of which took 
longer but variable time (10-180 min, from a set to a set) to achieve the peak RSP 
concentrations in the brain. Furthermore, the mean plasma AUC0–3 h tended to be higher when 
RSP was administered in the tested nanoemulsions compared to both control nanoemulsion 
RSP-LS75Sh and RSP solution, thus indicating an increased availability of RSP from 
nanoemulsions containing P80, PL188 or SHS15 as co-emulsifiers. Based on mean AUC0–3 h 
values, relative bioavailability (Frel) as well as absolute bioavailablity (Fabs) of RSP in plasma, 
the investigated nanoemulsions could be ranked in the following order: RSP-PL188Sh > 
RSP-P80Sh > RSP-SHS15Sh > RSP-LS75Sh. 
The data obtained for brain tissue showed that there were high inter-individual variations of 
RSP concentrations at various time points, which could have masked apparent differences 
between tested RSP formulations. Significant difference (F(4,10) = 6.241, p = 0.009) was 
detected only for RSP-P80Sh nanoemulsion which produced higher mean brain RSP 
concentrations than RSP-SHS15Sh and RSP-LS75Sh formulations and RSP solution at 40 
min post-injection. A tendency of increased brain concentrations of RSP formulated in RSP-
P80Sh and RSP-PL188Sh nanoemulsions at the last time point (3 h after the dose), which in 
both cases was true for two of three sets of data, suggests that there might have been a time-
consuming process such as, inter alia, receptor-mediated endocytosis/transcytosis, which 
promoted increased RSP uptake from these nanoemulsions into brain with time. As proposed 
by Kreuter (2001) for delivery of nanoparticles into brain, nanoemulsion droplets could have 
entered the brain by adsorption on brain capillary walls combined with increased retention in 
brain capillaries, creating higher concentration gradient which would enhance the transport 
across the brain capillary endothelial cells. Nanoemulsion droplets covered by combined 
lecithin/P80 or lecithin/PL188 emulsifier film could have also been uptaken into brain 
through endocytosis and/or transcytosis enabled by plasma apolipoproteins anchored on the 
droplet surface (Kreuter, 2001; Wohlfart et al., 2012; Kasongo et al., 2011). Finally, 
inhibition of P-glycoprotein efflux system at the BBB by P80 (Kreuter, 2001; Prabhakar et 
al., 2013) and probably by PL188 (Kabanov et al., 2003; Wohlfart et al., 2012) could have 
added to the tendency of improvement of RSP brain levels from P80- and PL188-containing 
nanoemulsions. 
As an index of brain drug targeting, the brain-to-plasma concentration ratio of RSP from 
various formulations was calculated at each time point (Fig. 7). It was evident that mean RSP 
concentrations in plasma following i.p. administration of RSP nanoemulsions or RSP solution 
exceeded those in brain at most of time points, which is not surprising taking into account 
relatively low lipophilicity of RSP (log P 3.04) as well as its efflux by P-glycoprotein 
expressed at the BBB (Aravagiri and Marder, 2002; Bundgaard et al., 2012). Nevertheless, 
the fact that brain-to-plasma concentration ratio of RSP tended to be  1 when it was 
administered in nanoemulsions RSP-LS75Sh (at 1 h) and RSP-P80Sh or RSP-PL188Sh (3 h 
post-injection) could indicate the potential of these nanoemulsion carriers for RSP targeting 
to the brain. 
There were no significant differences in either of brain pharmacokinetic parameters (Cmax, 
Tmax, AUC0–t) calculated for four RSP nanoemulsions and RSP solution. Nevertheless, it is 
important to note that among the nanoemulsions the highest mean brain AUC0–3 h was seen 
with the formulation RSP-P80Sh, followed by the RSP-LS75Sh and RSP-PL188Sh, and 
finally by the RSP-SHS15Sh nanoemulsion (Table 2). Since all nanoemulsion types were 
very similar regarding their measured physicochemical parameters – Z-Ave, PDI, and ZP 
(Table S2, Supplementary material), this trend could be ascribed primarily to the differences 
in the specific surface properties caused by the presence of co-emulsifiers with different 
structures, especially polyoxyethylene chains length, and consequently behavior at the oil–
water interface. These findings suggest that neither droplet size, nor surface charge, but 
particle surface, i.e., the interfacial composition of the stabilizing layer, was the crucial factor 
responsible for BBB passage and differences in pharmacokinetic profiles of RSP. 
In general, the total brain levels (AUC0–3 h, brain) of RSP were lower than those found in 
plasma (AUC0–3 h, plasma), which resulted in an overall brain-to-plasma exposure ratio, that is, 
brain-to-plasma partition coefficient (Kp),  1 (Table 2). Although the co-emulsifier-free 
nanoemulsion (RSP-LS75Sh) tended to have the greatest Kp value, it could not be stated that 
this nanoemulsion delivered RSP to the brain significantly better than other formulations. 
Accordingly, the therapeutic availability, also referred to as relative uptake rate (R), was 
another parameter taken into account. As evidenced by the R values shown in Table 2, the 
brain availability of RSP following nanoemulsion administration, excepting RSP-SHS15Sh, 
was enhanced compared to the i.p. solution. The higher brain uptake might have resulted 
from the simple diffusion through the BBB of free RSP released from nanoemulsion and 
endocytosis/transcytosis of RSP-loaded nanoemulsion droplets. Furthermore, the mean 
AUC0–3 h in the brain of RSP-P80Sh nanoemulsion was 2-fold higher than for RSP solution 
and 1.4–7.4-fold higher than for other tested nanoemulsions, indicating that P80 might be a 
promising surfactant for enhancing RSP brain delivery. Although the developed 
nanoemulsions showed certain capability to target the brain, further experiments are needed 
to elucidate their in vivo fate and effect on RSP pharmacodynamics. 
 
4. Conclusions 
 
In this work, a systematic design of experiments approach was successfully applied to better 
understand the formulation and preparation of nanoemulsions as potential carriers for brain 
drug targeting. The results of performed general factorial design showed significant 
individual as well as mutual effect of tested formulation and process factors (co-emulsifier 
type, aqueous phase type, HPH method) affecting critical quality attributes (droplet size, PDI, 
ZP) of nanoemulsions. Based on physicochemical properties and stability during 4 months of 
storage at 25 °C and after autoclaving, the most suitable nanoemulsion formulations typically 
containing sodium oleate in aqueous phase and P80, PL188 or SHS15 as co-emulsifier were 
selected, loaded with RSP as a model drug, and prepared by hot HPH method. AFM 
corroborated the size measurement results, demonstrating uniform distribution of spherical 
droplets with the mean diameter below 200 nm, whereas DSC and FTIR analyses indicated 
that RSP was molecularly dispersed in the investigated nanoemulsions, without chemical 
interactions with other ingredients. 
In vivo pharmacokinetic study demonstrated different brain profiles of RSP after i.p. 
administration of selected nanoemulsions costabilized with different co-emulsifiers, 
suggesting that nanoemulsion droplet surface, i.e., composition of the stabilizing film, was 
probably the key factor determining the BBB passage of RSP. From the targeting point of 
view, it could be deduced that among the tested nanoemulsions, the P80-costabilized one 
could be preferable for RSP delivery to the brain. However, additional investigations are 
necessary to validate the observed potential of developed nanoemulsions for improving RSP 
brain targeting after parenteral administration and to determine whether these findings may 
have clinical relevance and significant influence on RSP therapeutic efficacy. 
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Figure captions 
Figure 1. Pareto plots for mean droplet size – Z-Ave (a), polydispersity index (b), and zeta 
potential (c) of designed nanoemulsions, along with the coefficient values and p values for 
the studied variables – A: co-emulsifier type; B: aqueous phase type; C: HPH method. 
Figure 2. Interaction graphs for the mean droplet size (Z-Ave) of designed nanoemulsions. 
Figure 3. Interaction graphs for the polydispersity index (PDI) of designed nanoemulsions. 
Figure 4. Interaction graphs for the zeta potential (ZP) of designed nanoemulsions. 
Figure 5. DSC thermograms of pure RSP, RSP-loaded (RSP-P80Sh) and blank (P80Sh) 
nanoemulsion (a); FTIR spectra of pure RSP, soybean lecithin (LS75), MCT–soybean oil 
(MCT–SO) mixture, RSP-loaded (RSP-P80Sh) and unloaded (P80Sh) nanoemulsion (b). 
Figure 6. AFM images of RSP-loaded nanoemulsion (RSP-P80Sh): error signal of 2 x 2 μm2 
area of the sample (a), 2D topography (b), 3D topography (c), and height profiles of two 
selected nanoemulsion droplets (d). 
Figure 7. Plasma and brain pharmacokinetic profiles and brain-to-plasma concentration 
ratios of RSP after intraperitoneal administration of RSP nanoemulsions (RSP-P80Sh, RSP-
PL188Sh, RSP-SHS15Sh, and RSP-LS75Sh) and RSP solution to rats (mean ± SEM, n = 3); 
*p < 0.05, compared to RSP-P80Sh, RSP-LS75Sh, and RSP solution (ANOVA, F(4,10) = 
6.581, p = 0.007); **p < 0.05, compared to RSP-P80Sh and RSP-SHS15Sh (Mann–Whitney 
U test); ***p < 0.05, compared to RSP-P80Sh, RSP-PL188Sh, and RSP-SHS15Sh 
nanoemulsions (Mann–Whitney U test). 
 
 
 
 
 
 
 
 
 
 
Table 1. 
General factorial design matrix. 
  Variables 
  Co-emulsifier 
type (A) 
Aqueous phase 
type (B) 
HPH method 
(C) 
Run Formulation 
code 
Actual 
level 
Coded 
level 
Actual 
level 
Coded 
level 
Actual 
level 
Coded 
level 
1 P80Pc P80 {1 0} PBS –1 Cold –1 
2 P80Ph     Hot 1 
3 P80Sc   SOS 1 Cold –1 
4 P80Sh     Hot 1 
5 PL188Pc PL188 {0 1} PBS –1 Cold –1 
6 PL188Ph     Hot 1 
7 PL188Sc   SOS 1 Cold –1 
8 PL188Sh     Hot 1 
9 SHS15Pc SHS15 {–1 –1} PBS –1 Cold –1 
10 SHS15Ph     Hot 1 
11 SHS15Sc   SOS 1 Cold –1 
12 SHS15Sh     Hot 1 
 
P80: polysorbate 80; PL188: poloxamer 188; SHS15: Solutol® HS 15; PBS: phosphate buffer 
solution; SOS: sodium oleate aqueous solution. 
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Table 2. 
Pharmacokinetic parameters of risperidone after intraperitoneal administration of selected 
risperidone-loaded nanoemulsions and risperidone solution (free risperidone) to rats (mean ± 
SEM, n = 3). 
 
Values are shown as means ± SEM (n = 3). DTI: drug targeting index (Kp RSP nanoemulsion/Kp 
RSP solution). 
 
 
 
 
 
 
  Formulation 
Parameter  RSP-P80Sh RSP-
PL188Sh 
RSP-
SHS15Sh 
RSP-LS75Sh RSP-solution 
 Plasma      
Cmax (ng/mL)  780.07 ± 
127.55 
781.00 ± 
34.87 
614.10 ± 
48.34 
573.96 ± 
14.62 
639.29 ± 
82.04 
Tmax (h)  0.31 ± 0.18 0.19 ± 0.07 0.11 ± 0.03 0.14 ± 0.03 0.11 ± 0.03 
AUC0–t (h ng/mL)  567.83 ± 
78.99 
642.79 ± 
75.97 
366.29 ± 
140.81 
265.49 ± 
26.94 
268.96 ± 
35.24 
CL (L/h/kg)  1.82 ± 0.23 1.60 ± 0.19 3.48 ± 0.97 3.84 ± 0.37 3.84 ± 0.45 
T1/2 (h)  1.53 ± 0.51 0.87 ± 0.13 1.11 ± 0.25 0.73 ± 0.17 0.92 ± 0.21 
Frel (%)  211.12 238.99 136.19 98.71 – 
Fabs (%)  77.21 87.40 49.81 36.10 36.57 
 Brain      
Cmax (ng/g)  292.96 ± 
106.76 
136.28 ± 
48.16 
170.87 ± 
22.92 
199.63 ± 
43.54 
158.09 ± 
27.17 
Tmax (h)  1.17 ± 0.92 1.11 ± 0.94 0.08 ± 0.00 0.44 ± 0.28 0.11 ± 0.03 
AUC0–t (h ng/g)  277.06 ± 
155.49 
150.29 ± 
101.36 
37.25 ± 
10.39 
195.39 ± 
96.81 
135.57 ± 
29.62 
Kp  0.51 ± 0.32 0.28 ± 0.21 0.13 ± 0.05 0.81 ± 0.46 0.51 ± 0.13 
DTI  1.00 0.54 0.25 1.57 – 
R  2.04 1.11 0.27 1.44 – 
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